Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MSI-H/dMMR + POLE mutation
i
Other names:
MSI-H, Microsatellite instability - high, dMMR, POLE1, DNA Polymerase Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit A, Polymerase (DNA) Epsilon Catalytic Subunit, DNA Polymerase II Subunit A, Polymerase (DNA Directed) Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit Protein, Polymerase (DNA Directed) Epsilon
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
5426
Related biomarkers:
Expression
Mutation
Others
‹
POLE mutation (27)
POLE V411L (3)
POLE P286R (2)
MSI-H/dMMR + KMT2D mutation (1)
POLE A456P (1)
POLE EDM (1)
POLE mutation + POLD1 mutation (1)
POLE S459F (0)
POLE mutation (27)
POLE V411L (3)
POLE P286R (2)
MSI-H/dMMR + KMT2D mutation (1)
POLE A456P (1)
POLE EDM (1)
POLE mutation + POLD1 mutation (1)
POLE S459F (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MSI-H/dMMR + POLE mutation
Gastric Cancer
MSI-H/dMMR + POLE mutation
Gastric Cancer
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
MSI-H/dMMR + POLE mutation
Colorectal Cancer
MSI-H/dMMR + POLE mutation
Colorectal Cancer
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
MSI-H/dMMR + POLE mutation
Solid Tumor
MSI-H/dMMR + POLE mutation
Solid Tumor
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
dostarlimab-gxly
Sensitive: C3 – Early Trials
dostarlimab-gxly
Sensitive
:
C3
MSI-H/dMMR + POLE mutation
Non Small Cell Lung Cancer
MSI-H/dMMR + POLE mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.